14 November 2023 in Journal of Human Hypertension
Alongside the lack of homogeneity among international guidelines and consensus documents on primary hyperaldosteronism, the National UK guidelines on hypertension do not provide extensive recommendations regarding the diagnosis and management of this condition. Local guidelines vary from area to area, and this is reflected in the current clinical practice in the UK. In an attempt to provide support to the clinicians involved in the screening of subjects with hypertension and clinical management of suspected cases of primary hyperaldosteronism the following document has been prepared on the behalf of the BIHS Guidelines and Information Service Standing Committee. Through remote video conferences, the authors of this document reviewed an initial draft which was then circulated among the BIHS Executive members for feedback. A survey among members of the BIHS was carried out in 2022 to assess screening strategies and clinical management of primary hyperaldosteronism in the different regions of the UK. Feedback and results of the survey were then discussed and incorporated in the final document which was approved by the panel after consensus was achieved considering critical review of existing literature and expert opinions. Grading of recommendations was not performed in light of the limited available data from properly designed randomized controlled trials.
24 December 2014 in Emergency Medicine Journal
Objective The Manchester Acute Coronary Syndromes (MACS) decision rule may enable acute coronary syndromes to be immediately ‘ruled in’ or ‘ruled out’ in the emergency department. The rule incorporates heart-type fatty acid binding protein (h-FABP) and high sensitivity troponin T levels. The rule was previously validated using a semiautomated h-FABP assay that was not practical for clinical implementation. We aimed to validate the rule with an automated h-FABP assay that could be used clinically. Methods In this prospective diagnostic cohort study we included patients presenting to the emergency department with suspected cardiac chest pain. Serum drawn on arrival was tested for h-FABP using an automated immunoturbidimetric assay (Randox) and high sensitivity troponin T (Roche). The primary outcome, a diagnosis of acute myocardial infarction (AMI), was adjudicated based on 12 h troponin testing. A secondary outcome, major adverse cardiac events (MACE; death, AMI, revascularisation or new coronary stenosis), was determined at 30 days. Results Of the 456 patients included, 78 (17.1%) had AMI and 97 (21.3%) developed MACE. Using the automated h-FABP assay, the MACS rule had the same C-statistic for MACE as the original rule (0.91; 95% CI 0.88 to 0.92). 18.9% of patients were identified as ‘very low risk’ and thus eligible for immediate discharge with no missed AMIs and a 2.3% incidence of MACE (n=2, both coronary stenoses). 11.1% of patients were classed as ‘high-risk’ and had a 92.0% incidence of MACE. Conclusions Our findings validate the performance of a refined MACS rule incorporating an automated h-FABP assay, facilitating use in clinical settings. The effectiveness of this refined rule should be verified in an interventional trial prior to implementation. Trial registration number UK CRN 8376.
9 December 2024 in Journal of Human Hypertension
People living with resistant hypertension (RH) are at high risk of adverse cardiovascular events. The British and Irish Hypertension Society has identified suspected RH as a condition for which specialist guidance may improve rates of blood pressure control and help clinicians identify those individuals who may benefit from specialist review. In this position statement we provide a practical approach for the investigation and management of adults with RH. We highlight gaps in the current evidence and identify important future research questions. Our aim is to support the delivery of high-quality and consistent care to people living with RH across the UK and Ireland.
1 November 2014 in Journal Of Hypertension
Objective: No universally accepted guideline exists for measurement of blood pressure for patients confined to bed. The aim was to establish areas of technique that might be open to standardization to improve measurement reliability similar to those used for office BP measurements. Methods: In-patient blood pressure measurement (IPBPM) was closely observed in 100 patients in a variety of medical wards during routine vital signs observation rounds, comparing the methods observed with current office BPM guidelines. Results: IPBPM, always taken initially with automated machines, was measured once only in 96% of patients. Around 7% patients were lying flat, 32% semi-reclined, 24% had their back unsupported, 15% crossed legs, 9% arms unsupported, 65% arm below heart level, 4% above, 36% incorrect cuff size for arm circumference, 43% bladder not centred over brachial artery and 14% had arrhythmia not documented by ward staff during the measurement. Staff and patients were conversing during 41% measurements. Conclusion: There is a lack of standardization of automated IPBPM technique including a failure to adhere to principles of measurement already established for office BP in a majority (97%) of patients. This may lead to potentially erroneous BP readings, which are an unreliable basis for clinical interpretation and decision making. There is a need for universal hospital-specific guidelines for IPBPM and programmes to train and monitor staff for adherence to these. Particular attention should be given to those factors well known to affect blood pressure measurement, including correct cuff size and placement, arm position and absence of talking during measurement as well as only using validated machines. Additional recommendations might include the routine use of manual BP readings where appropriate (such as with very low or irregular heart rates), BP measured in both arms on admission and the arm with the highest BP used thereafter and recording the side of IPBPM and patient position. We recommend that a task force is commissioned to develop universal guidelines for this important part of clinical assessment.
28 June 2024 in Journal of Human Hypertension
National and international hypertension guidelines recommend that adults with young-onset hypertension (aged <40 years at diagnosis) are reviewed by a hypertension specialist to exclude secondary causes of hypertension and optimise therapeutic regimens. A recent survey among UK secondary care hypertension specialist physicians highlighted variations in the investigation of such patients. In this position statement, the British and Irish Hypertension Society seek to provide clinicians with a practical approach to the investigation and management of adults with young-onset hypertension. We aim to ensure that individuals receive consistent and high-quality care across the UK and Ireland, to highlight gaps in the current evidence, and to identify important future research questions.
9 January 2024 in Journal of Human Hypertension
In the UK, most adults with hypertension are managed in Primary Care. Referrals to Secondary Care Hypertension Specialists are targeted to patients in whom further investigations are likely to change management decisions. In this position statement the British and Irish Hypertension Society provide clinicians with a framework for referring patients to Hypertension Specialists. Additional therapeutic advice is provided to optimise patient management whilst awaiting specialist review. Our aim is to ensure that referral criteria to Hypertension Specialists are consistent across the UK and Ireland to ensure equitable access for all patients.